ProShares UltraShort Health Care
4 hedge funds and large institutions have $350K invested in ProShares UltraShort Health Care in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 0 closing their positions.
1,839% more capital invested
Capital invested by funds: $18.1K → $350K (+$332K)
91% more call options, than puts
Call options by funds: $120M | Put options by funds: $62.7M
33% more funds holding
Funds holding: 3 → 4 (+1)
5.26% more ownership
Funds ownership: 0.6% → 5.85% (+5.3%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
+$332K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$5.96K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$77 |
RXD Hedge Fund Activity: Q1 2023 in Review
4 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort Health Care (RXD) for Q1 2023, worth a combined $350K — up 1,839% from $18.1K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new RXD positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Envestnet Asset Management, opening a new position worth an estimated $332K. The largest seller was UBS Group, cutting an estimated $5.96K.
- 4 institutional investors held ProShares UltraShort Health Care (RXD) as of Q1 2023, up from 3 in Q4 2022.
- Funds reported $350K of ProShares UltraShort Health Care stock for Q1 2023, up 1,839% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort Health Care positions in Q1 2023 and 0 closed out, a net change of +1 holder.
- The largest ProShares UltraShort Health Care buyer in Q1 2023 was Envestnet Asset Management, an estimated $332K added.
- The largest ProShares UltraShort Health Care seller in Q1 2023 was UBS Group, an estimated $5.96K sold.
Based on aggregated 13F filings for Q1 2023.